GlassScriptPhysician profile
Scott Richard Silva
NPI 1487097390
$1,452.97
in general payments reported to CMS, 2019-2025
26 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $245 · 2021: $314 · 2022: $53.77 · 2023: $164 · 2024: $38.63 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $181.43 | 2019-2023 | Tagrisso |
| Boston Scientific Corporation | $167.52 | 2021-2025 | Spaceoar Vue System - 10ml |
| Amgen INC. | $139.44 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.57 | 2019-2023 | |
| Foundation Medicine, INC. | $102.33 | 2019-2021 | |
| Seagen INC. | $102.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $77.60 | 2019-2023 | Welireg, Keytruda, Lynparza |
| Eisai INC. | $62.49 | 2020-2021 | |
| Angiodynamics, INC. | $61.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $54.99 | 2020 | |
| Clovis Oncology, INC. | $48.14 | 2019-2020 | |
| Blue Earth Diagnostics | $48.10 | 2025 | Posluma |
| Reflexion Medical, INC. | $34.40 | 2023 | Reflexion Medical Radiotherapy System |
| Stemline Therapeutics INC. | $31.06 | 2025 | Elzonris |
| Novartis Pharmaceuticals Corporation | $30.21 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.37 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $23.05 | 2023 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $20.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.48 | 2023 | Ninlaro |
| Genentech USA, INC. | $19.51 | 2023 | Tecentriq |
| Pfizer INC. | $19.39 | 2024 | |
| Daiichi Sankyo INC. | $19.24 | 2024 | Enhertu |
| Astellas Pharma US INC | $18.35 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.98 | 2019 | |
| Rigel Pharmaceuticals, INC. | $14.56 | 2019 | |
| Ge Healthcare | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.